CD8A and neoplasm: This larger number of mutations opens up the possibility to load synthetic RNAs coding for a large number of different tumor-derived neoantigens via intravenously administered RNA–lipoplexes onto the immune system where they may evoke effector and memory T-cell responses, and mediate IFNα-dependent rejection of tumors.30 Alternatively, synthetic naked DNA can be administered to skin-resident dendritic cells via micropinocytosis, which then prime antigen-specific CD8+ T cells.31